Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives

SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common hematological malignancy. Initially, prognosis for MM patients was poor. However, due to the development of novel treatment regimens, their clinical outcomes have significantly improved. One of the milestones in the treatment of MM was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulig, Piotr, Milczarek, Sławomir, Bakinowska, Estera, Szalewska, Laura, Baumert, Bartłomiej, Machaliński, Bogusław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913106/
https://www.ncbi.nlm.nih.gov/pubmed/36765919
http://dx.doi.org/10.3390/cancers15030963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913106/
https://www.ncbi.nlm.nih.gov/pubmed/36765919
http://dx.doi.org/10.3390/cancers15030963

Ejemplares similares